ArticleJournal of the American Chemical Society2025
A Trifunctional, Rare-Earth Theranostic Chelator Platform to Enable Diagnostic Nuclear Imaging, Surgical Resection, and Radiotherapy.
Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Surface bioengineering of lanthanide nanoparticles for theranostic applications: From hydrophilic modification to multimodal imaging and therapy.Materials today. Bio · 2026Review
- Single Molecule EuJournal of the American Chemical Society · 2026Article
- Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we establish a single-molecule, trifunctional platform compatible with diagnostic positron emission tomography (PET), optical imaging-assisted intrasurgical resection, and chelation of radiotherapeutic rare-earth nuclides. Building on previous pyridylalkynylaryl (PEPA) antenna scaffolds, mono- and bisantenna analogs incorporating either PEPA or methoxy-substituted MEPA chromophores were prepared to assess the role of pyridylalkynylaryl number and polyethylene glycol (PEG) substitution on photophysical and biological performance. Photophysical characterization with Eu(III) revealed that antenna truncation had minimal impact on quantum yields and Cerenkov radiation energy transfer (CRET) imaging while substantially improving water solubility. Biodistribution studies with Y-86-labeled analogs identified [
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.